<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408967</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62206-016</org_study_id>
    <nct_id>NCT00408967</nct_id>
  </id_info>
  <brief_title>Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.</brief_title>
  <official_title>An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if either of two doses of EMD 273066 when given
      with a low dose of cyclophosphamide will result in a second time to progression that is as
      long or longer than the first time to progression
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Th trial got cancelled and no subjects signed informed consent form (ICF); study design not
    appropriate any longer.
  </why_stopped>
  <start_date type="Actual">December 31, 2006</start_date>
  <completion_date type="Actual">May 31, 2008</completion_date>
  <primary_completion_date type="Actual">May 31, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Tucotuzumab celmoleukin (EMD 273066)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucotuzumab celmoleukin (EMD 273066)</intervention_name>
    <arm_group_label>Tucotuzumab celmoleukin (EMD 273066)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Age 18 years or older

          -  Have histologically documented ovarian carcinoma (including primary peritoneal
             carcinoma)

          -  Have archival tumor tissue available for EpCAM expression determination by
             immunohistochemistry

          -  Received first-line platinum-based chemotherapy of up to 8 cycles (approximately 15 to
             24 weeks)

          -  Experienced a complete response to first-line platinum-based chemotherapy

          -  Experienced a platinum-free interval of at least 6 but not more than 24 months
             starting at the end of the last cycle of first-line chemotherapy until recurrence

               -  Treatment with Avastin (bevacizumab) is permitted during first-line
                  platinum-based chemotherapy through TTP and platinum-based reinduction therapy up
                  to 28 days prior to start of EMD 273066

          -  Experienced a partial or complete response after up to 8 cycles of second-line
             platinum-based chemotherapy

          -  Have a CT/MRI scan within 4 weeks prior to starting treatment

          -  Be able to start cyclophosphamide and EMD 273066 treatment within 3 to 5 weeks of
             completion of second-line chemotherapy

          -  KPS ≥70%

          -  No clinical history of significantly impaired renal function or chronic kidney
             disease. Must have an estimated glomerular filtration rate ≥50 mL/min determined by
             the Cockgroft-Gault-formula

          -  WBC count ≥2.5x10³/µL (or total granulocytes ≥1x10³/µL)

          -  Absolute lymphocyte count (ALC) ≥0.5x103/µL

          -  Platelet count ≥100,000/µL

          -  Hemoglobin (Hgb) level ≥9 g/dl

          -  ALT and AST ≤2.5xULN, total bilirubin &lt;1.5xULN

          -  Serum sodium, potassium and phosphorus within normal limits

          -  Serum amylase within normal limits

          -  Serologic testing within 4 weeks prior to starting study treatment with negative
             results for hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis
             B virus (HBV) demonstrated by negative hepatitis B core antibody (HBc Ab) and
             hepatitis B surface antigen (HbsAg)

          -  Negative pregnancy test and willingness to use effective contraception for the study
             duration and 1 month thereafter if of procreative potential

        Exclusion Criteria:

          -  Dyspnea at rest, exercise intolerance

          -  In any subject with clinically significant non-malignant pulmonary disease: Pulmonary
             function testing (to include Forced Vital Capacity [FVC] and 1-second Forced
             Expiratory Volume [FEV-1]) showing &lt;70% of predicted values for FVC or FEV-1 and/or
             DLCO &lt;50%.

          -  In any subject with pulmonary or pleural metastatic disease: Arterial oxygen
             saturation at rest measured transcutaneously on room air &lt; 90% or increased risk for
             respiratory compromise related to IL2 exposure in the judgment of the investigator.

          -  ECG with evidence of clinically significant disease within 4 weeks prior to starting
             study treatment

          -  Cardiac stress test (e.g., exercise or pharmacological thallium test; exercise or
             pharmacological echocardiography) with abnormal results within 4 weeks prior to
             starting treatment in subjects who have a history of coronary heart disease
             (myocardial infarction, angina pectoris or pathologic coronary angiography)

          -  Any current evidence of congestive heart failure with NY Heart Association Grade 2
             through 4 or echocardiogram with a left ventricular ejection fraction &lt;45% or other
             signs of clinical significant heart disease

          -  History of repeated and clinically relevant episodes of syncope or other paroxysmal,
             ventricular, or other clinically significant arrhythmias

          -  Evidence of active brain metastases

          -  Previous malignancy other than ovarian cancer in the last 5 years except basal cell
             cancer of the skin or pre-invasive cancer of the cervix

          -  Pregnant or lactating female

          -  An immediate need for palliative radiotherapy or systemic corticosteroid therapy

          -  Significant active infection

          -  Major surgery, chemotherapy, or radiation within 21 days of starting study treatment

          -  Received another experimental drug within 28 days of starting study treatment

          -  Uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥100 mmHg) or hypotension
             (systolic ≤90 mmHg)

          -  Presence of medically significant third space fluids such as pleural or pericardial
             effusions or edema of toxicity grade ≥2 according to the National Cancer Institute
             Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 [17].

               -  Exception allowed for disease-related peritoneal ascites unless patient requires
                  frequent and repetitive paracentesis management.

        Previous diagnosis of an autoimmune disease involving a major organ system

          -  Transplant recipient on immunosuppressive therapy

          -  Acute esophageal or gastroduodenal ulcers

          -  History of prior therapy or a serious uncontrolled medical disorder that in the
             Investigator's opinion would impair participation in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian</keyword>
  <keyword>Cancer</keyword>
  <keyword>Epithelial</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Platinum</keyword>
  <keyword>Second-line therapy</keyword>
  <keyword>Maintenance Therapy</keyword>
  <keyword>Biologic</keyword>
  <keyword>Targeted Therapy</keyword>
  <keyword>Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

